Recursion Pharmaceuticals

Yahoo Finance • 3 hours ago

Expanded Citeline Data Partnership and CMO Transition Could Be A Game Changer For Recursion Pharmaceuticals (RXRX)

In March 2026, Citeline announced an expanded strategic partnership with Recursion Pharmaceuticals to integrate Citeline's real-world data and evidence into Recursion’s tech-enabled drug discovery and development platform, aiming to improv... Full story

Yahoo Finance • 23 hours ago

1 Beaten-Down AI Stock to Buy and 1 to Avoid

Key Points Alphabet is already a leader in AI and boasts attractive growth avenues beyond this industry. Recursion Pharmaceuticals has a long way to go before demonstrating that its approach works. 10 stocks we like better than Alphabet ›... Full story

Yahoo Finance • 2 days ago

2 AI Healthcare Stocks to Buy Right Now

While the advent of artificial intelligence (AI) has obviously changed the world, not every utilization of AI has necessarily made the world a better place. Indeed, a recent survey from PwC indicates that 56% of CEOs aren't yet seeing any... Full story

Yahoo Finance • 11 days ago

Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026

The past several weeks have been challenging ones for the overall market. But they've been downright miserable ones for most artificial intelligence (AI) stocks. Microsoft shares are down more than 20% from last year's peak, for instance,... Full story

Yahoo Finance • 11 days ago

Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026

Key Points In retrospect, it’s clear that most AI stocks’ inflated valuations were never fully justified. The technology isn’t going away, though. It’s evolving into one with more practical and marketable uses. Some companies are better p... Full story

Yahoo Finance • 12 days ago

Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.

Key Points Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor can build from scratch.10 s... Full story

Yahoo Finance • 20 days ago

Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller mentioned that Cathie Wood invested in the stock, Cramer remarked, “That’s, it’s a let down, big let down. Came on the sh... Full story

Yahoo Finance • 25 days ago

Can This AI Stock Bounce Back in 2026?

Artificial intelligence (AI) is all the rage on Wall Street these days, but not every AI stock is equally successful. Some of the bigger names in the field, like Nvidia, have seen their shares soar in recent years, while other, smaller one... Full story

Yahoo Finance • 27 days ago

BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Low Risk Penny Stocks to Buy Now. On February 27, Bank of America Securities reiterated a Hold rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) but lowered the price target... Full story

Yahoo Finance • last month

Recursion Pharmaceuticals (RXRX) Hits Clinical Milestones as 2025 Revenue Grows to $74.7M

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, Recursion Pharmaceuticals reported its financial results for Q4 and the full year 2025, highlighting a pivotal transiti... Full story

Yahoo Finance • last month

Recursion (RXRX) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Feb. 25, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Najat KhanChief Financial Officer — Ben TaylorChief Scientific Officer — Dave Hallett Need a quote from a Motley Foo... Full story

Yahoo Finance • last month

Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Evolution and Platform Validation Management characterizes the current phase as an 'inflection point' where the focus shifts from building AI models to transl... Full story

Yahoo Finance • last month

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical and preclinical programs advancing wi... Full story

Yahoo Finance • last month

Recursion Pharmaceuticals, Inc. (RXRX) Advances AI Drug Discovery Amid Market Shifts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory filings indicated that Nvidia had divested a... Full story

Yahoo Finance • last month

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

If you bought into Figma(NYSE: FIG), CoreWeave(NASDAQ: CRWV), or Recursion Pharmaceuticals (NASDAQ: RXRX) at last year's peak, you're not feeling pretty good right now. The three fallen growth stocks are trading 52%, 82%, and 72% below the... Full story

Yahoo Finance • last month

Cathie Wood Pours $24 Million to This AI Software Stock

This article first appeared on GuruFocus. Cathie Wood's ARK Invest added to Figma (NYSE:FIG) and trimmed DraftKings (NASDAQ:DKNG) on Feb. 19, as part of a broader portfolio reshuffle. ARK funds bought about $24 million of Figma shares af... Full story

Yahoo Finance • last month

Applied Digital (APLD) Loses 4.9% as Nvidia Disposes of Shares

We recently published 10 Losing Stocks in an Otherwise Optimistic Market. Applied Digital Corp. (NASDAQ:APLD) was one of the worst performers on Wednesday. Applied Digital extended its losing streak to a sixth straight day on Wednesday, d... Full story

Yahoo Finance • last month

Major Backers Exit As Recursion Deepens Commitment To REC-102 Pipeline

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Major investors Nvidia and Novo Holdings A/S have fully exited their positions in Recursion Pharma... Full story

Yahoo Finance • last month

Recursion Pharmaceuticals and Applied Digital shares fall after Nvidia exits stakes

[Man walking to the direction of the arrows in front of red wall] baona/E+ via Getty Images * Recursion Pharmaceuticals (RXRX [https://seekingalpha.com/symbol/RXRX]) shares fell 13% in premarket trading on Wednesday, while Applied Digit... Full story

Yahoo Finance • 2 months ago

This $4 Stock Could Be Your Ticket to Millionaire Status

What's the best next use of artificial intelligence (AI)? Plenty of people would say drug development. And they'd arguably be right. That's not something for down the road, though, when AI is more refined. Recursion Pharmaceuticals(NASDAQ... Full story